CN1780622A - 作为5－羟色胺再摄取抑制剂的4－(2－苯基硫烷基－苯基)－哌啶衍生物 - Google Patents

作为5－羟色胺再摄取抑制剂的4－(2－苯基硫烷基－苯基)－哌啶衍生物 Download PDF

Info

Publication number
CN1780622A
CN1780622A CNA2004800091749A CN200480009174A CN1780622A CN 1780622 A CN1780622 A CN 1780622A CN A2004800091749 A CNA2004800091749 A CN A2004800091749A CN 200480009174 A CN200480009174 A CN 200480009174A CN 1780622 A CN1780622 A CN 1780622A
Authority
CN
China
Prior art keywords
fluoro
phenylsulfanyl
phenyl
piperidine
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800091749A
Other languages
English (en)
Chinese (zh)
Inventor
B·邦-安德森
A·皮施尔
M·约尔根森
T·鲁兰德
T·布赖恩斯滕博尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36091716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1780622(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN1780622A publication Critical patent/CN1780622A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2004800091749A 2003-04-04 2004-04-02 作为5－羟色胺再摄取抑制剂的4－(2－苯基硫烷基－苯基)－哌啶衍生物 Pending CN1780622A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300520 2003-04-04
DKPA200300520 2003-04-04

Publications (1)

Publication Number Publication Date
CN1780622A true CN1780622A (zh) 2006-05-31

Family

ID=36091716

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800091749A Pending CN1780622A (zh) 2003-04-04 2004-04-02 作为5－羟色胺再摄取抑制剂的4－(2－苯基硫烷基－苯基)－哌啶衍生物

Country Status (10)

Country Link
KR (1) KR101107536B1 (pt)
CN (1) CN1780622A (pt)
AR (1) AR043965A1 (pt)
BR (1) BRPI0408647A (pt)
CL (1) CL2004000725A1 (pt)
EA (1) EA010869B1 (pt)
IS (1) IS2676B (pt)
NZ (1) NZ541859A (pt)
UA (1) UA81472C2 (pt)
ZA (1) ZA200507181B (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970408A (zh) * 2007-12-14 2011-02-09 H.隆德贝克有限公司 4-[2，3-二氟-6-(2-氟-4-甲基-苯基硫基)-苯基]-哌啶
CN105348204A (zh) * 2015-11-18 2016-02-24 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
AP2002002481A0 (en) * 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970408A (zh) * 2007-12-14 2011-02-09 H.隆德贝克有限公司 4-[2，3-二氟-6-(2-氟-4-甲基-苯基硫基)-苯基]-哌啶
CN105348204A (zh) * 2015-11-18 2016-02-24 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途

Also Published As

Publication number Publication date
AR043965A1 (es) 2005-08-17
EA200501577A1 (ru) 2006-04-28
ZA200507181B (en) 2007-03-28
CL2004000725A1 (es) 2005-02-18
UA81472C2 (en) 2008-01-10
KR101107536B1 (ko) 2012-01-31
EA010869B1 (ru) 2008-12-30
IS7996A (is) 2005-08-22
IS2676B (is) 2010-09-15
BRPI0408647A (pt) 2006-03-07
NZ541859A (en) 2008-10-31
KR20050119681A (ko) 2005-12-21

Similar Documents

Publication Publication Date Title
CN1038932C (zh) 取代的哌啶类化合物的立体选择性制备方法
CN1273467C (zh) β－内酰胺化合物、这些化合物的制备方法以及含有这些化合物的降血清胆固醇药
CN1196680C (zh) 新的多巴胺神经传递调节剂
CN1061963A (zh) 用作药物的4-取代的呱啶类
CN1143848C (zh) 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物
CN1365359A (zh) 苯并呋喃哌嗪和苯并呋喃基高哌嗪:血清素激动剂
CN1082040A (zh) 吲哚类
CN1355782A (zh) 苯衍生物、其制备方法以及含有它们的药用组合物
CN1758909A (zh) 作为新MDM2－p53抑制剂的取代的哌啶类
CN1067655A (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物
CN1223652A (zh) 作为钠通道调节剂的环醚化合物
CN1780815A (zh) 芳族羟苯基和芳族硫基苯基衍生物
CN1022914C (zh) 新的1，3-二取代哌啶衍生物的制备方法
CN101076517A (zh) 作为多巴胺神经传递调节剂的新的取代的哌啶类
CN1809558A (zh) 作为5ht4－拮抗剂的4－(氨甲基)－哌啶苯甲酰胺
CN1246110A (zh) 芳基哌啶子基丙醇和芳基哌嗪子基丙醇衍生物和含有它们的药物
CN1906163A (zh) 作为肾素抑制剂的4－苯基哌啶衍生物
CN1261431C (zh) 2h－1－苯并吡喃衍生物、它们的制备方法及其药物组合物
CN1054600A (zh) 新的胆碱酯酶抑制剂三环—环胺
CN1407982A (zh) 血清素能苯并呋喃
CN1309722C (zh) 抗抑郁的杂环稠合的苯并二噁烷的环烷基胺衍生物
CN1041583A (zh) 蝇蕈碱受体拮抗剂
CN1777585A (zh) 作为5－羟色胺再摄取抑制剂的4－(2－苯硫基－苯基)－1,2,3,6－四氢吡啶衍生物
CN1194977A (zh) 苯氧基甲基哌啶衍生物
CN1303373A (zh) 用于治疗抑郁症的n－芳氧基乙基胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1092060

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1092060

Country of ref document: HK